Search results
Found 21853 matches for
The RECOVERY trial was established in March as a randomised clinical trial to test a range of potential treatments for COVID-19, including lopinavir-ritonavir, an antiviral treatment commonly used to treat HIV. There was no significant difference in the primary endpoint of 28-day mortality, and the results were consistent in different subgroups of patients. There was also no evidence of beneficial effects on the risk of progression to mechanical ventilation or length of hospital stay. The trial Steering Committee concluded that there is no beneficial effect of lopinavir-ritonavir in patients hospitalised with COVID-19 and closed that treatment arm.
Peter Horby
FRS Peter Horby - Moh Family Foundation Professor of Emerging Infections and Global Health
Brian Angus
BSc, MBChB, DTM&H, FRCP, MD, FFTM Brian Angus - Professor of Practice, Medical Education and Reader in Infectious Diseases
